Agenus (AGEN) News Today $3.54 -0.07 (-1.94%) Closing price 01/30/2025 04:00 PM EasternExtended Trading$3.59 +0.05 (+1.53%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period William Blair Has Positive Outlook of Agenus FY2024 EarningsJanuary 31 at 1:17 AM | americanbankingnews.comSaponiQx Publishes Breakthrough on Scalable, Stable QS-21 Adjuvant Production for Pandemic Vaccine DevelopmentJanuary 30 at 12:13 PM | uk.finance.yahoo.comFY2024 Earnings Forecast for Agenus Issued By William BlairAgenus Inc. (NASDAQ:AGEN - Free Report) - Investment analysts at William Blair upped their FY2024 EPS estimates for shares of Agenus in a note issued to investors on Monday, January 27th. William Blair analyst M. Phipps now expects that the biotechnology company will post earnings of ($14.59) perJanuary 30 at 7:32 AM | marketbeat.comAgenus reports publication of data from bot/bal combination in JOCOJanuary 30 at 1:44 AM | markets.businessinsider.comAgenus reports promising sarcoma study resultsJanuary 30 at 1:44 AM | msn.comAgenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic SarcomasJanuary 29 at 12:37 PM | businesswire.comH.C. Wainwright Sticks to Their Hold Rating for Agenus (AGEN)January 27, 2025 | markets.businessinsider.comAgenus presents updated bot/bal data at ASCO-GI, says H.C. WainwrightJanuary 27, 2025 | markets.businessinsider.comAgenus (NASDAQ:AGEN) Receives "Neutral" Rating from HC WainwrightJanuary 25, 2025 | americanbankingnews.comAgenus (AGEN) Receives a Hold from H.C. WainwrightJanuary 23, 2025 | markets.businessinsider.comAgenus reports promising colorectal cancer treatment dataJanuary 22, 2025 | msn.comAgenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced DiseaseJanuary 22, 2025 | businesswire.comHC Wainwright Reiterates Neutral Rating for Agenus (NASDAQ:AGEN)HC Wainwright restated a "neutral" rating on shares of Agenus in a report on Wednesday.January 22, 2025 | marketbeat.comSaponiQx, Probius, and Ginkgo Bioworks Unite to Revolutionize Vaccine Adjuvant DevelopmentJanuary 21, 2025 | businesswire.comAgenus Inc. (NASDAQ:AGEN) Given Consensus Rating of "Hold" by AnalystsShares of Agenus Inc. (NASDAQ:AGEN - Get Free Report) have been given a consensus recommendation of "Hold" by the six brokerages that are covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation tJanuary 10, 2025 | marketbeat.comPromising Potential for Agenus in Oncology: Buy Rating Reinforced by Strong CRC and Gastric Cancer Therapy ProspectsJanuary 8, 2025 | markets.businessinsider.comAgenus Inc. (NASDAQ:AGEN) Short Interest Up 6.5% in DecemberAgenus Inc. (NASDAQ:AGEN - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 2,930,000 shares, a growth of 6.5% from the November 30th total of 2,750,000 shares. Approximately 13.1% of the shares of the company are short sold. Based on an average daily trading volume, of 494,100 shares, the short-interest ratio is presently 5.9 days.December 31, 2024 | marketbeat.comAgenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric CancersDecember 18, 2024 | businesswire.comAgenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Hold" by AnalystsAgenus Inc. (NASDAQ:AGEN - Get Free Report) has earned an average recommendation of "Hold" from the six analysts that are currently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating on the compaDecember 16, 2024 | marketbeat.comVaccine Adjuvants Market with Business Strategy, Key Drivers, Opportunities, Top Key Companies Analysis and ForecastDecember 13, 2024 | theglobeandmail.comTanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With AgenusDecember 12, 2024 | finance.yahoo.comHC Wainwright Estimates Agenus' Q4 Earnings (NASDAQ:AGEN)Agenus Inc. (NASDAQ:AGEN - Free Report) - Investment analysts at HC Wainwright boosted their Q4 2024 EPS estimates for Agenus in a research note issued to investors on Thursday, December 5th. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will earn ($2.62) per sharDecember 9, 2024 | marketbeat.comWalleye Capital LLC Takes $1 Million Position in Agenus Inc. (NASDAQ:AGEN)Walleye Capital LLC acquired a new stake in Agenus Inc. (NASDAQ:AGEN - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 182,939 shares of the biotechnology company's stock, valued at approximately $1,003,000. Walleye CDecember 7, 2024 | marketbeat.comQ1 Earnings Estimate for Agenus Issued By HC WainwrightAgenus Inc. (NASDAQ:AGEN - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Agenus in a report released on Thursday, December 5th. HC Wainwright analyst E. Bodnar forecasts that the biotechnology company will earn ($2.29) per share for the quartDecember 6, 2024 | marketbeat.comAgenus Hold Rating: Strategic Focus on MSS-CRC Amid Financial and Regulatory UncertaintiesDecember 6, 2024 | markets.businessinsider.comAgenus announces strategic realignmentDecember 6, 2024 | markets.businessinsider.comAgenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce CostsDecember 5, 2024 | businesswire.comAgenus Inc. (NASDAQ:AGEN) Sees Large Drop in Short InterestAgenus Inc. (NASDAQ:AGEN - Get Free Report) was the recipient of a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 2,620,000 shares, a decrease of 6.4% from the October 31st total of 2,800,000 shares. Currently, 11.8% of the shares of the company are sold short. Based on an average daily volume of 452,300 shares, the days-to-cover ratio is currently 5.8 days.December 2, 2024 | marketbeat.comAgenus (NASDAQ:AGEN) Earns "Neutral" Rating from HC WainwrightHC Wainwright reissued a "neutral" rating and set a $7.00 target price on shares of Agenus in a research report on Friday.November 29, 2024 | marketbeat.comCautious Hold Rating on Agenus Amid Strategic Realignment and Financial ChallengesNovember 27, 2024 | markets.businessinsider.comAgenus secures $22M mortgage, announces strategic realignmentNovember 27, 2024 | markets.businessinsider.comAgenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug DevelopmentNovember 27, 2024 | benzinga.comAgenus Secures $22 Million Mortgage and Announces Strategic Operational RealignmentNovember 27, 2024 | businesswire.comB. Riley Has Negative Outlook for Agenus FY2024 EarningsAgenus Inc. (NASDAQ:AGEN - Free Report) - Stock analysts at B. Riley cut their FY2024 earnings per share estimates for shares of Agenus in a research report issued to clients and investors on Monday, November 18th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will postNovember 20, 2024 | marketbeat.comPromising Developments and Strategic Financing Enhance Agenus’s Buy Rating Amidst Stock VolatilityNovember 19, 2024 | markets.businessinsider.comAgenus Inc. (NASDAQ:AGEN) Short Interest UpdateAgenus Inc. (NASDAQ:AGEN - Get Free Report) was the target of a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 2,800,000 shares, a decline of 10.5% from the October 15th total of 3,130,000 shares. Based on an average daily volume of 393,300 shares, the days-to-cover ratio is currently 7.1 days. Currently, 13.2% of the company's shares are sold short.November 17, 2024 | marketbeat.comWilliam Blair Issues Negative Outlook for Agenus EarningsAgenus Inc. (NASDAQ:AGEN - Free Report) - Equities researchers at William Blair lowered their Q4 2024 EPS estimates for Agenus in a report issued on Tuesday, November 12th. William Blair analyst M. Phipps now expects that the biotechnology company will post earnings of ($2.85) per share for the qNovember 15, 2024 | marketbeat.comAgenus Inc.November 14, 2024 | wsj.comAgenus Inc (AGEN) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges While ...November 14, 2024 | finance.yahoo.comAgenus Clinical Trials Prospects: Navigating Uncertainties and Financial RisksNovember 13, 2024 | markets.businessinsider.comQ3 2024 Agenus Inc Earnings CallNovember 13, 2024 | finance.yahoo.comAgenus (AGEN) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | finance.yahoo.comAgenus Inc. Reports Progress in Immunotherapy DevelopmentNovember 13, 2024 | markets.businessinsider.comAgenus Inc (AGEN) Q3 2024 Earnings: EPS Miss, Revenue at $25.1M vs. $61.48M EstimateNovember 12, 2024 | gurufocus.comAgenus (NASDAQ:AGEN) Price Target Lowered to $7.00 at HC WainwrightHC Wainwright dropped their target price on shares of Agenus from $8.00 to $7.00 and set a "neutral" rating on the stock in a report on Tuesday.November 12, 2024 | marketbeat.comAgenus Inc. (AGEN) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comAgenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL DevelopmentNovember 12, 2024 | finance.yahoo.comInsights Ahead: Agenus's Quarterly EarningsNovember 11, 2024 | benzinga.comEarnings To Watch: Agenus Inc (AGEN) Reports Q3 2024 ResultNovember 11, 2024 | finance.yahoo.comAgenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024November 7, 2024 | finance.yahoo.com Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address AGEN Media Mentions By Week AGEN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AGEN News Sentiment▼0.470.71▲Average Medical News Sentiment AGEN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AGEN Articles This Week▼126▲AGEN Articles Average Week Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies XOMA News Vanda Pharmaceuticals News Verastem News Sangamo Therapeutics News Lexicon Pharmaceuticals News Achieve Life Sciences News Regulus Therapeutics News Fortress Biotech News SAB Biotherapeutics News Curis News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AGEN) was last updated on 1/31/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThe #1 Stock for Trump’s Second Term?Imagine how much money you could make if you bought all of the top performing stocks during Trump's second ter...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AGEN Stock Alerts